

Alert	Concomitant use of a thiazide diuretic is recommended. Avoid higher doses where possible.
Indication	Treatment of neonatal hyperinsulinaemic hypoglycaemia (transient or persistent).
Action	Opens potassium-ATP channels on pancreatic beta-cells to inhibit insulin secretion. Opening of these channels also occurs in cardiac and vascular smooth muscle leading to decrease in blood pressure and potential for cardiorespiratory deterioration.
Drug Type	Antihypertensive, antidiuretic benzothiadiazine.
Trade Name	Oral: Proglycem. Intravenous: DBL Diazoxide Injection BP.
Presentation	Oral: Diazoxide 10 mg/mL solution compounded in house by the Pharmacy department; 50 mg/mL commercial oral preparation available as an unregistered product. Intravenous: DBL Diazoxide Injection BP 300 mg/20 mL ampoule.
Dosage / Interval	5–15 mg/kg/day. Can be given as 2–5 mg/kg/dose every 8 hours or 2.5–7.5 mg/kg/dose every 12 hours.
Maximum daily dose	Neonates: 15 mg/kg/day. Children: Up to 30 mg/kg/day but caution exceeding 20 mg/kg/day.
Route	Oral. Intravenous.
Preparation/Dilution	Oral solution: Shake well before use. Intravenous: Do not dilute (15 mg/mL).
Administration	Oral: Administer after feeds (preferred). Intravenous: Administer over at least 30 seconds. DO NOT administer by intramuscular or subcutaneous injection (alkaline solution).
Monitoring	Monitor blood pressure and blood glucose levels during initial treatment. Monitor for sodium and fluid retention (urine output, electrolytes and weight). Consider monitoring albumin and liver function. ¹
Contraindications	Hypersensitivity to thiazide derivatives.
Precautions	Avoid sodium and water overload. Concomitant use of a thiazide diuretic is recommended. Avoid higher doses where possible. Use with caution in premature infants – increased risk of cardiorespiratory complications; Use with caution in jaundice – may displace bilirubin from albumin. Reduce dose in infants with renal impairment. Use with caution in infants with hepatic impairment. Use with caution in mechanical hypertension, e.g. secondary to aortic coarctation or arteriovenous shunt. Use with caution in pulmonary hypertension.
Drug Interactions	Concomitant administration of diuretics may result in potentiation of the hyperglycaemic, hyperuricaemic or hypotensive effect of diazoxide.
Adverse Reactions	Tolerance to diazoxide is usually good. Severe adverse effects include sodium and fluid retention which may precipitate congestive heart failure in patients with compromised cardiac reserve. Usually responds to diuretic therapy. Life-threatening episodes of pulmonary hypertension were observed in some neonates receiving diazoxide. ² Prematurity and higher diazoxide doses are risk factors for cardiovascular side effects. ³ Severe hypotension can be controlled with sympathomimetic agents if necessary. With prolonged use, hypertrichosis can sometimes be marked and distressing in young children, but will be reversible after treatment cessation. Haematological side effects are very rare with the usual doses. Overdose of diazoxide produces hyperglycaemia and possibly ketoacidosis which should be treated promptly with insulin and restoration of fluid and electrolyte balance.
Compatibility	Do not mix with other fluids or drugs.

Incompatibility	Do not mix with other fluids or drugs.
Stability	Discard remaining IV solution after use.
Storage	Ampoules: Store below 25 C. Protect from light. Avoid excessive heat and freezing. Oral solution: As per advice from Pharmacy.
Special Comments	Concomitant use of a thiazide diuretic is recommended to counter sodium and fluid retention from use of diazoxide. ^{4,5} Oral diazoxide is not registered in Australia. Complete a category A Special Access Scheme form and obtain parental consent.
Evidence summary	As per NMF Consensus Group. Refer to reference manual or electronic version.
References	As per NMF Consensus Group. Refer to reference manual or electronic version.

Original version Date: 6/10/2016	Author: Neonatal Medicines Formulary Consensus Group
Current Version number: 1	Current Version Date: 6/10/2016
Risk Rating: Medium	Due for Review: 6/10/2019
Approval by: JHCH CQ&PCC	Approval Date: 22/11/2016